Sun Pharmaceutical Industries Limited
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Sun Pharmaceutical Industries Limited - overview
Established
1983
Location
Mumbai, Maharashtra, India
Primary Industry
Pharmaceuticals
About
Sun Pharmaceutical Industries Limited is a leading global pharmaceutical company that develops and manufactures a broad range of specialty and generic medicines, addressing diverse healthcare needs across various therapeutic areas. Sun Pharmaceutical Industries Limited is a prominent pharmaceutical manufacturer based in Mumbai, India, specializing in generic and specialty medications. The company was founded by Danish Kamaal and Meesum Hassan. Abhay Gandhi currently serves as the CEO.
Sun Pharma operates globally, focusing on regions like North America, Europe, Asia, and Africa, with a significant presence in the United States. The company has not reported any significant pivots in business strategy or any known subsidiaries. Sun Pharmaceutical Industries Ltd. is a global pharmaceutical company specializing in a diverse array of high-quality generic and specialty medicines.
Its core product offerings encompass a wide variety of therapeutic areas, including cardiology, psychiatry, neurology, gastroenterology, and dermatology. The company's portfolio includes both prescription medications and over-the-counter products, catering to a broad client base of hospitals, healthcare providers, and pharmacies. Key geographical markets for Sun Pharma's products include the United States, Canada, India, and various countries across Europe, Asia, Africa, and Latin America, ensuring comprehensive global outreach in delivering healthcare solutions. In the fiscal year 2024, Sun Pharmaceutical Industries Ltd.
reported a revenue of USD 5,769. 24 mn and an EBITDA of USD 1,553. 51 mn. The company generates revenue primarily through the sale of its pharmaceutical products to a diverse clientele, including hospitals, clinics, and retail pharmacies.
Sun Pharma's transactions typically involve direct sales to distributors and wholesalers, who subsequently supply the end products to healthcare providers and consumers. The company markets several flagship products that significantly contribute to its financial performance, structured to meet varying demand in key markets. Sun Pharmaceutical Industries Ltd. has outlined its future growth strategy, focusing on the development of new products in various therapeutic areas.
The company aims to expand its market presence in emerging regions such as Southeast Asia and Latin America by 2025. Recent funding will support these initiatives by enhancing research and development capabilities, enabling the launch of innovative products that address unmet medical needs. Sun Pharma's strategy emphasizes strengthening partnerships and collaborations to facilitate market entry and product development.
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceuticals
Website
www.sunpharma.com
Total Amount Raised
Subscriber access only
Sun Pharmaceutical Industries Limited - timeline of key events
Sun Pharmaceutical Industries Limited - financials
| Fiscal Year Ended | Mar 31, 2012 | Mar 31, 2013 | Mar 31, 2014 | Mar 31, 2015 | Mar 31, 2016 | Mar 31, 2017 | Mar 31, 2018 | Mar 31, 2019 | Mar 31, 2020 | Mar 31, 2021 | Mar 31, 2022 | Mar 31, 2023 | Mar 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 80,194,900,000 | 112,998,600,000 | 160,803,600,000 | 274,334,400,000 | 285,177,000,000 | 315,784,400,000 | 264,894,600,000 | 290,659,100,000 | 328,375,000,000 | 334,981,400,000 | - | - | - |
| % Revenue Growth (YoY) | - | 40.9% | 42.3% | 70.6% | 4.0% | 10.7% | (16.1%) | 9.7% | 13.0% | 2.0% | - | - | - |
| EBITDA (USD) | 34,780,700,000 | 44,638,600,000 | 48,300,900,000 | 79,198,000,000 | 79,897,600,000 | 103,412,500,000 | 50,247,000,000 | 53,632,200,000 | 70,175,300,000 | 48,436,700,000 | - | - | - |
| Operating Income (USD) | 31,869,100,000 | 41,276,900,000 | 44,208,600,000 | 67,250,800,000 | 69,762,400,000 | 90,765,000,000 | 36,169,900,000 | 37,655,100,000 | 49,852,800,000 | 27,686,500,000 | - | - | - |
| Operating Margin | 39.7% | 36.5% | 27.5% | 24.5% | 24.5% | 28.7% | 13.7% | 13.0% | 15.2% | 8.3% | - | - | - |
| % EBITDA Margin | 43.4% | 39.5% | 30.0% | 28.9% | 28.0% | 32.7% | 19.0% | 18.5% | 21.4% | 14.5% | - | - | - |
| NET Income (USD) | 30,421,700,000 | 34,693,400,000 | 38,790,000,000 | 54,882,100,000 | 58,303,800,000 | 78,363,000,000 | 26,337,900,000 | 32,093,200,000 | 41,867,900,000 | 22,846,800,000 | - | - | - |
| % Net Margin | 37.9% | 30.7% | 24.1% | 20.0% | 20.4% | 24.8% | 9.9% | 11.0% | 12.8% | 6.8% | - | - | - |
Sun Pharmaceutical Industries Limited - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.